G1 Therapeutics Inc. [GTHX] stock was sold by Malik Rajesh at the price of US$3942.0


G1 Therapeutics Inc.’s recent filing unveils that its Chief Medical Officer Malik Rajesh unloaded Company’s shares for reported $3942.0 on Jan 05. In the deal valued at $5.41 per share,729 shares were sold. As a result of this transaction, Malik Rajesh now holds 102,739 shares worth roughly $ 0.35 million.

From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".


Then, Hanson James S. sold 729 shares, generating $3,942 in total proceeds. Upon selling the shares at $5.41, the General Counsel now owns 41,087 shares.

Before that, Moses Jennifer K. sold 729 shares. G1 Therapeutics Inc. shares valued at $3,942 were divested by the CFO at a price of $5.41 per share. As a result of the transaction, Moses Jennifer K. now holds 57,820 shares, worth roughly $0.2 million.

JP Morgan upgraded its G1 Therapeutics Inc. [GTHX] rating to a Neutral from a an Underweight in a research note published on Friday, January 30, 2023; the price target was increased to $10 from $7. PT values the company’s stock at a premium of 66.0 to its Friday closing price. A number of analysts have revised their coverage, including Needham’s analysts, who remained covering the stock and in early January has reiterated a ‘”a Buy”‘ rating for it. JP Morgan also remained covering GTHX and has decreased its forecast on November 04, 2021 with a “an Underweight” recommendation from previously “Neutral” rating.

Price Performance Review of GTHX

On Friday, G1 Therapeutics Inc. [NASDAQ:GTHX] saw its stock fall -6.08% to $3.40. On the same session, the stock had its day’s lowest price of $3.38, but rose to a high of $3.5808. Over the last five days, the stock has lost -11.23%. G1 Therapeutics Inc. shares have fallen nearly -37.38% since the year began. Nevertheless, the stocks have fallen -65.16% over the past one year. While a 52-week high of $17.49 was reached on 02/02/23, a 52-week low of $3.20 was recorded on 02/13/23. SMA at 50 days reached $5.89, while 200 days put it at $8.25. A total of 1.0 million shares were traded, compared to the trading of 1.12 million shares in the previous session.

Levels Of Support And Resistance For GTHX Stock

The 24-hour chart illustrates a support level at 3.33, which if violated will result in even more drops to 3.25. On the upside, there is a resistance level at 3.53. A further resistance level may holdings at 3.65. The Relative Strength Index (RSI) on the 14-day chart is 29.30, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.42, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 95.75%. Stochastics %K at 7.93% indicates the stock is a buying.

How much short interest is there in G1 Therapeutics Inc.?

A steep rise in short interest was recorded in G1 Therapeutics Inc. stocks on Jan 30, 2023, growing by 0.55 million shares to a total of 3.12 million shares. Yahoo Finance data shows the prior-month short interest on Dec 29, 2022 was 2.57 million shares. There was a rise of 17.63%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 6.80% of the overall stock float, the days-to-cover ratio (short ratio) rose to 3.07.

G1 Therapeutics Inc. [GTHX] – Who Are The Largest Shareholders?

In filings from Fisher Asset Management LLC, it is revealed that the company now owns 2,809,444 shares, or roughly 5.55% of the outstanding GTHX shares. In other words, the investor’s shares have fallen by -125,888 from its previous 13-F filing of 2935332.0. Additionally, The Vanguard Group, Inc. increased 12.33% of its stake after which the total value it holdings stand at $15,010,707, while JPMorgan Investment Management, I added 0.39% of its stake to hold $13.97 million in the firm. Over the last quarter, Millennium Management LLC purchased 499,363 shares of G1 Therapeutics Inc., while BlackRock Fund Advisors bought 142,334 shares. At present, Woodline Partners LP is holding 1,028,967 shares valued at $8.21 million. Marshall Wace LLP owned 994,988 shares of the company at the time of its most recent 13F filing, worth $7.94 million.

According to FactSet, G1 Therapeutics Inc.’s share price will average $13.29 in the next year, based on opinions of analysts polled by the firm. This is up nearly 203.87 percent from its previous closing price of $3.62. Analysts expect G1 Therapeutics Inc. stock to reach the higher price of $24.00, while the lowest price estimate is $5.00. However, 8 analysts have rated GTHX stock as a Buy in their predictions for 2023.


Please enter your comment!
Please enter your name here